Possibilities of combined nasal drugs in symptomatic therapy of allergic rhinitis in adolescent children
| Autor: | E. P. Karpova, D. A. Tulupov |
|---|---|
| Jazyk: | ruština |
| Rok vydání: | 2021 |
| Předmět: | |
| Zdroj: | Медицинский совет, Vol 0, Iss 11, Pp 101-108 (2021) |
| Druh dokumentu: | article |
| ISSN: | 2079-701X 2658-5790 |
| DOI: | 10.21518/2079-701X-2021-11-101-108 |
| Popis: | This article provides an overview of current views on the problem of allergic rhinitis (AR) in children. Modern data on the epidemiology of AR and the main comorbid conditions are highlighted. It has been noted that adolescence is the peak incidence of AR. Despite the similar clinical manifestations of AR in adolescent children, it should be borne in mind that patients in this age group represent a unique population with needs and perceptions of problems that are different from those of adults and young children. Mental perception of the symptoms of the disease is more often more pronounced in adolescents than in other age groups. This manifests itself in a large negative impact on both sleep and rest patterns, as well as on learning activity and exam results. The work of a doctor with patients of this age group requires the most rationalized approach. Based on the data of the latest consensus documents, the role of I and II generation antihistamines, intranasal antihistamines and intranasal glucocorticosteroids was assessed. The possibilities of symptomatic therapy of symptomatic moderate and severe AR with the help of nasal sprays based on a fixed combination of intranasal glucocorticosteroids and antihistamines have been evaluated in more detail. The available data from clinical studies of the use of a nasal spray based on a fixed combination of mometasone furoate and olopatadine are reviewed. Based on the above material, it was concluded that nasal sprays of a fixed combination of mometasone furoate and olopatadine are effective means of starting therapy for moderate to severe seasonal and perennial AR in children over 12 years of age. Such combination drugs can reduce the severity of AR symptoms with a relatively low risk of developing adverse events. |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|